Abstract
The data presented here support the research article “Association of serum mimecan with angiographic coronary collateralization in patients with stable coronary artery disease and chronic total occlusion” (Shen et al., 2016) [1] where elevated circulating mimecan levels reflected poor angiographic coronary collateralization in such patients. The data included in this article are composed by one figure and consist of (1) validation of serum mimecan measurement by assessing inter- and intra-assay variability in 45 samples; (2) findings on the relation of clinical and angiographic characteristics and biochemical parameters to coronary collateralization in 559 patients; (3) the diagnostic value of serum mimecan for poor collateralization, which was derived from plotting receiver-operating characteristic curves and logistic regression analysis.
Highlights
The data presented here support the research article “Association of serum mimecan with angiographic coronary collateralization in patients with stable coronary artery disease and chronic total occlusion” (Shen et al, 2016) [1] where elevated circulating mimecan levels reflected poor angiographic coronary collateralization in such patients
Association between serum mimecan and coronary collateralization was assessed in 559 patients with stable angina and chronic total occlusion People's Republic of China
Data on low coronary collateralization in stable angina patients who have concurrently elevated circulating mimecan levels are suited for studies investigating the mechanism of collateral development
Summary
The data included a cohort of 648 consecutive patients with stable angina and chronic total occlusion (43 months) of at least one major epicardial coronary artery. The participants were prospectively entered a database [2]. Information on patient demographics, clinical and angiographic feature and in-hospital management was collected retrospectively, whereas clinical outcome during follow-up was identified prospectively. For the purpose of the study that the data are based on, 89 patients were excluded by the exclusion criteria, and 559 patients were eligible for final analysis (Fig. 1)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
